IFNG and melanoma: Six stage IIB/C or stage IVM1 a/b melanoma patients were evaluated; all patients generated de novo immune responses against neoepitopes following vaccination, as measured by ex vivo IFNγ ELISPOT of peripheral blood mononuclear cells.